Phase II trials of imatinib mesylate and docetaxel in patients with metastatic non-small cell lung cancer and head and neck squamous cell carcinoma

Journal of Thoracic Oncology

Volumn 6, Issue 12, 2011, Pages 2104-2111

  Tsao, Anne S ^a   Liu, Suyu ^a   Fujimoto, Junya ^a   Wistuba, Ignacio I ^a   Lee, J Jack ^a   Marom, Edith M ^a   Charnsangavej, Chusilp ^a   Fossella, Frank V ^a   Tran, Hai T ^a   Blumenschein, George R ^a   Papadimitrakopoulou, Vassiliki ^a   Kies, Merrill S ^a   Hong, Waun K ^a   Stewart, David J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Docetaxel; Head and neck squamous cell carcinoma; Imatinib mesylate; Non small cell lung cancer

Indexed keywords

DOCETAXEL; IMATINIB; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DYSPHAGIA; DYSPNEA; FACE EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEAD AND NECK CARCINOMA; HUMAN; HYPOKALEMIA; HYPOMAGNESEMIA; LUNG NON SMALL CELL CANCER; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

EID: 81755179381     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31822e7256     Document Type: Article

References (47)

1. Pietras K, Sjoblom T, Rubin K, et al. PDGF receptors as cancer drug targets. Cancer Cell 2003;3:439-443. (Pubitemid 38340290)
2. Uehara H, Kim SJ, Karashima T, et al. Effects of blocking plateletderived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases. J Natl Cancer Inst 2003;95: 458-470. (Pubitemid 36432420)
3. Pietras K, Ostman A, Sjoquist M, et al. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res 2001;61:2929-2934. (Pubitemid 32691937)
4. Kim SJ, Uehara H, Yazici S, et al. Simultaneous blockade of plateletderived growth factor-receptor and epidermal growth factor-receptor signaling and systemic administration of paclitaxel as therapy for human prostate cancer metastasis in bone of nude mice. Cancer Res 2004;64: 4201-4208. (Pubitemid 38802424)
5. Pietras K, Rubin K, Sjoblom T, et al. Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res 2002;62:5476-5484.
6. Griffon-Etienne G, Boucher Y, Brekken C, et al. Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications. Cancer Res 1999;59:3776-3782. (Pubitemid 29381886)
7. Ringel I, Horwitz SB. Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol. J Natl Cancer Inst 1991;83:288-291.
8. Bissery MC, Guenard D, Gueritte-Voegelein F, et al. Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Res 1991;51:4845-4852.
9. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095-2103. (Pubitemid 30324363)
10. Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000;18:2354-2362. (Pubitemid 30415821)
11. Catimel G, Verweij J, Mattijssen V, et al. Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. Ann Oncol 1994;5:533-537.
12. Dreyfuss AI, Clark JR, Norris CM, et al. Docetaxel: an active drug for squamous cell carcinoma of the head and neck. J Clin Oncol 1996;14: 1672-1678. (Pubitemid 26134226)
13. Couteau C, Chouaki N, Leyvraz S, et al. A phase II study of docetaxel in patients with metastatic squamous cell carcinoma of the head and neck. Br J Cancer 1999;81:457-462. (Pubitemid 29458799)
14. Mathew P, Thall PF, Jones D, et al. Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer. J Clin Oncol 2004;22: 3323-3329. (Pubitemid 41103689)
15. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216. (Pubitemid 30099779)
16. Behrens C, Feng L, Kadara H, et al. Expression of interleukin-1 receptor-associated kinase-1 in non-small cell lung carcinoma and preneoplastic lesions. Clin Cancer Res 2010;16:34-44.
17. Tang X, Kadara H, Behrens C, et al. Abnormalities of the TITF-1 lineage-specific oncogene in NSCLC: implications in lung cancer pathogenesis and prognosis. Clin Cancer Res 2011;17:2434-2443.
18. Ninck S, Reisser C, Dyckhoff G, et al. Expression profiles of angiogenic growth factors in squamous cell carcinomas of the head and neck. Int J Cancer 2003;106:34-44. (Pubitemid 36750385)
19. Kawai T, Hiroi S, Torikata C. Expression in lung carcinomas of platelet-derived growth factor and its receptors. Lab Invest 1997;77:431-436. (Pubitemid 27508614)
20. Antoniades HN, Galanopoulos T, Neville-Golden J, et al. Malignant epithelial cells in primary human lung carcinomas coexpress in vivo platelet-derived growth factor (PDGF) and PDGF receptor mRNAs and their protein products. Proc Natl Acad Sci USA 1992;89:3942-3946.
21. Rosenthal E, McCrory A, Talbert M, et al. Elevated expression of TGF-beta1 in head and neck cancer-associated fibroblasts. Mol Carcinog 2004;40:116-121. (Pubitemid 38736537)
22. Chang JT, Chen IH, Liao CT, et al. A reverse transcription comparative real-time PCR method for quantitative detection of angiogenic growth factors in head and neck cancer patients. Clin Biochem 2002;35:591-596. (Pubitemid 36009325)
23. Gleich LL, Srivastava L, Gluckman JL. Plasma platelet-derived growth factor: preliminary study of a potential marker in head and neck cancer. Ann Otol Rhinol Laryngol 1996;105:710-712. (Pubitemid 26304003)
24. Mathew P, Thall PF, Bucana CD, et al. Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases. Clin Cancer Res 2007;13:5816-5824. (Pubitemid 47583906)
25. Yardley DA, Burris HA 3rd, Markus T, et al. Phase II trial of docetaxal plus imatinib mesylate in the treatment of patients with metastatic breast cancer. Clin Breast Cancer 2009;9:237-242.
26. Matei D, Emerson RE, Schilder J, et al. Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis: a Hoosier Oncology Group trial. Cancer 2008;113:723-732.
27. Coleman RL, Broaddus RR, Bodurka DC, et al. Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers. Gynecol Oncol 2006;101: 126-131.
28. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-1597. (Pubitemid 41079796)
29. Huang CH, Williamson SK, Van Veldhuizen PJ, et al. Potential role of platelet-derived growth factor receptor inhibition using imatinib in combination with docetaxel in the treatment of recurrent non-small cell lung cancer. J Thorac Oncol 2011;6:372-377.
30. Glisson BS, Murphy BA, Frenette G, et al. Phase II trial of docetaxel and cisplatin combination chemotherapy in patients with squamous cell carcinoma of the head and neck. J Clin Oncol 2002;20:1593-1599. (Pubitemid 34260540)
31. Matei D, Chang DD, Jeng MH. Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on plateletderived growth factor receptor alpha and Akt inactivation. Clin Cancer Res 2004;10:681-690. (Pubitemid 38174008)
32. Hagisawa S, Mikami T, Sato Y. Docetaxel-induced apoptosis in the mitotic phase: electron microscopic and cytochemical studies of human leukemia cells. Med Electron Microsc 1999;32:167-174. (Pubitemid 30182205)
33. Clarke SJ, Rivory LP. Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet 1999;36:99-114. (Pubitemid 29121684)
34. Kelly RJ, Draper D, Chen CC, et al. A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer. Clin Cancer Res 2011;17:569-580.
35. Chiu LY, Ko JL, Lee YJ, et al. L-type calcium channel blockers reverse docetaxel and vincristine-induced multidrug resistance independent of ABCB1 expression in human lung cancer cell lines. Toxicol Lett 2010; 192:408-418.
36. Harmsen S, Meijerman I, Febus CL, et al. PXR-mediated induction of P-glycoprotein by anticancer drugs in a human colon adenocarcinomaderived cell line. Cancer Chemother Pharmacol 2010;66:765-771.
37. Thomas J, Wang L, Clark RE, et al. Active transport of imatinib into and out of cells: implications for drug resistance. Blood 2004;104:3739-3745. (Pubitemid 39564452)
38. Burger H, van Tol H, Brok M, et al. Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps. Cancer Biol Ther 2005;4:747-752. (Pubitemid 41351174)
39. Widmer N, Colombo S, Buclin T, et al. Functional consequence of MDR1 expression on imatinib intracellular concentrations. Blood 2003; 102:1142. (Pubitemid 36917818)
40. van Zuylen L, Verweij J, Nooter K, et al. Role of intestinal P-glycoprotein in the plasma and fecal disposition of docetaxel in humans. Clin Cancer Res 2000;6:2598-2603. (Pubitemid 30482093)
41. Mahon FX, Belloc F, Lagarde V, et al. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 2003;101:2368-2373. (Pubitemid 36304670)
42. Vlahovic G, Ponce AM, Rabbani Z, et al. Treatment with imatinib improves drug delivery and efficacy in NSCLC xenografts. Br J Cancer 2007;97:735-740. (Pubitemid 47396288)
43. McCarty MF, Somcio RJ, Stoeltzing O, et al. Overexpression of PDGF-BB decreases colorectal and pancreatic cancer growth by increasing tumor pericyte content. J Clin Invest 2007;117:2114-2122. (Pubitemid 47219556)
44. Mathew P, Thall PF, Wen S, et al. Dynamic change in phosphorylated platelet-derived growth factor receptor in peripheral blood leukocytes following docetaxel therapy predicts progression-free and overall survival in prostate cancer. Br J Cancer 2008;99:1426-1432.
45. Donnem T, Al-Saad S, Al-Shibli K, et al. Prognostic impact of plateletderived growth factors in non-small cell lung cancer tumor and stromal cells. J Thorac Oncol 2008;3:963-970.
46. Donnem T, Al-Saad S, Al-Shibli K, et al. Co-expression of PDGF-B and VEGFR-3 strongly correlates with lymph node metastasis and poor survival in non-small-cell lung cancer. Ann Oncol 2010;21:223-231.
47. Wu E, Palmer N, Tian Z, et al. Comprehensive dissection of PDGFPDGFR signaling pathways in PDGFR genetically defined cells. PLoS One 2008;3:e3794.